CODX - コ・ダイアグノスティックス (Co-Diagnostics Inc.) コ・ダイアグノスティックス

 CODXのチャート


 CODXの企業情報

symbol CODx
会社名 Co-Diagnostics Inc (コ・ダイアグノスティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Co-Diagnostics Inc. is a molecular diagnostics company. The Company is engaged in developing manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis a drug resistant tuberculosis test hepatitis B and C Malaria dengue human immunodeficiency virus and Zika virus all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.   コ・ダイアグノスティックスは米国の医療関連企業。主に、医療診断における試薬の開発・製造・販売に従事する。核酸分子の検出および分析の診断テストに使用される試薬を開発、完結型ラボ・システムを販売する。また、病気や遺伝的疾患の治療のため、DNAベ―スの試験プラットフォ―ムを開発する。本社所在地はユタ州ソルト・レ―ク・シティ―。   Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
本社所在地 2401 S. Foothill Drive Suite D Salt Lake City UT 84109 USA
代表者氏名 Dwight H. Egan ドワイト・エガン
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 801-278-9769
設立年月日 41365
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数 15人
url www.codiagnostics.com
nasdaq_url https://www.nasdaq.com/symbol/codx
adr_tso
EBITDA EBITDA(百万ドル) -5.87956
終値(lastsale) 2.3054
時価総額(marketcap) 28467141.4458
時価総額 時価総額(百万ドル) 27.78306
売上高 売上高(百万ドル) 0.02460
企業価値(EV) 企業価値(EV)(百万ドル) 26.25479
当期純利益 当期純利益(百万ドル) -8.08090
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Co-Diagnostics Inc revenues increased from $2K to $19K. Net loss increased 72% to $2.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 46% to $655K (expense) Sales and marketing increase of 26% to $239K (expense).

 CODXのテクニカル分析


 CODXのニュース

   Co-Diagnostics, Inc. Announces Second Quarter 2021 Earnings Release Date And Webcast  2021/08/04 15:30:00 Co-Diagnostics
   Co-Diagnostics Inc Shares Close the Week 38.3% Higher - Weekly Wrap  2021/07/24 09:37:09 Kwhen Finance
Co-Diagnostics Inc (CODX) shares closed this week 38.3% higher than it did at the end of last week. The stock is currently up 13.3% year-to-date, down 50.4% over the past 12 months, and up 81.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 rose 0.2%. Trading Activity Shares traded as high as $11.20 and as low as $7.69 this week.Shares closed 70.6% below its 52-week high and 30.1% above its 52-week low.Trading volume this week was 341.6% higher than the 10-day average and 778.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 1.2% higher than its 5-day moving average, 8.6% higher than its 20-day moving average, and 2.2% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -67.8% The company's stock price performance over the past 12 months lags the peer average by -218.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -20.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Co-Diagnostics gets Republic of Korea patent for its CoPrimer technology  2021/07/22 14:27:15 Seeking Alpha
   Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer Patent  2021/07/22 13:30:00 Co-Diagnostics
   Proactive news headlines including Co-Diagnostics, Esports Entertainment, Versus Systems and Plurilock Security  2021/06/18 17:36:00 Intrado Digital Media
New York , June 18, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
   Co-Diagnostics, Inc. Announces Second Quarter 2021 Earnings Release Date And Webcast  2021/08/04 15:30:00 Co-Diagnostics
   Co-Diagnostics Inc Shares Close the Week 38.3% Higher - Weekly Wrap  2021/07/24 09:37:09 Kwhen Finance
Co-Diagnostics Inc (CODX) shares closed this week 38.3% higher than it did at the end of last week. The stock is currently up 13.3% year-to-date, down 50.4% over the past 12 months, and up 81.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 rose 0.2%. Trading Activity Shares traded as high as $11.20 and as low as $7.69 this week.Shares closed 70.6% below its 52-week high and 30.1% above its 52-week low.Trading volume this week was 341.6% higher than the 10-day average and 778.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 1.2% higher than its 5-day moving average, 8.6% higher than its 20-day moving average, and 2.2% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -67.8% The company's stock price performance over the past 12 months lags the peer average by -218.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -20.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Co-Diagnostics gets Republic of Korea patent for its CoPrimer technology  2021/07/22 14:27:15 Seeking Alpha
   Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer Patent  2021/07/22 13:30:00 Co-Diagnostics
   Proactive news headlines including Co-Diagnostics, Esports Entertainment, Versus Systems and Plurilock Security  2021/06/18 17:36:00 Intrado Digital Media
New York , June 18, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
   Proactive news headlines including Co-Diagnostics, Esports Entertainment, Versus Systems and Plurilock Security  2021/06/18 17:36:00 Intrado Digital Media
New York , June 18, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
   How The Salt Lake Tribune investigated the connection between the SEC and Co-Diagnostics  2021/06/18 17:12:46 The Salt Lake Tribune
The Salt Lake Tribune needs the public''s financial donations to continue producing quality investigative work.
   Co-Diagnostics, Inc. (CODX) Fell Out Of Favor With Hedge Funds  2021/06/18 16:11:37 Insider Monkey
   Regulatory actions for June 18, 2021  2021/06/18 16:00:00 BioWorld
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Co-Diagnostics, Hecin, Holista Colltech.
   Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test  2021/06/18 14:42:09 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コ・ダイアグノスティックス CODX Co-Diagnostics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)